Tamoxifen in Malignant Melanoma

Richard A. Nesbit; Robert L. Woods; Martin H.N. Tattersall; Richard M. Fox; John F. Forbes; Ian R. Mackay; M. Goodyear

doi:10.1056/NEJM197911293012218

Tamoxifen in Malignant Melanoma

Richard A. Nesbit, Robert L. Woods, Martin H.N. Tattersall, Richard M. Fox, John F. Forbes, Ian R. Mackay, M. Goodyear

Résultat de recherche: Letter › examen par les pairs

46 Citations (Scopus)

Résumé

To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.¹ We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

Langue d'origine	English
Pages (de-à)	1241-1242
Nombre de pages	2
Journal	New England Journal of Medicine
Volume	301
Numéro de publication	22
DOI	https://doi.org/10.1056/NEJM197911293012218
Statut de publication	Published - nov. 29 1979
Publié à l'externe	Oui

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Case Reports
Letter

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1056/NEJM197911293012218

Autres fichiers et liens

Citer

@article{ba47060e5ce0418ea7b69cfde64d5e6e,

title = "Tamoxifen in Malignant Melanoma",

abstract = "To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.",

author = "Nesbit, {Richard A.} and Woods, {Robert L.} and Tattersall, {Martin H.N.} and Fox, {Richard M.} and Forbes, {John F.} and Mackay, {Ian R.} and M. Goodyear",

year = "1979",

month = nov,

day = "29",

doi = "10.1056/NEJM197911293012218",

language = "English",

volume = "301",

pages = "1241--1242",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Tamoxifen in Malignant Melanoma

AU - Nesbit, Richard A.

AU - Woods, Robert L.

AU - Tattersall, Martin H.N.

AU - Fox, Richard M.

AU - Forbes, John F.

AU - Mackay, Ian R.

AU - Goodyear, M.

PY - 1979/11/29

Y1 - 1979/11/29

N2 - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

AB - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

UR - http://www.scopus.com/inward/record.url?scp=0018602550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018602550&partnerID=8YFLogxK

U2 - 10.1056/NEJM197911293012218

DO - 10.1056/NEJM197911293012218

M3 - Letter

C2 - 503125

AN - SCOPUS:0018602550

SN - 0028-4793

VL - 301

SP - 1241

EP - 1242

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 22

ER -

Tamoxifen in Malignant Melanoma

Résumé

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer